Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03829462
Title Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)
Acronym NEXT-REGIRI
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Institut du Cancer de Montpellier - Val d'Aurelle
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.